Literature DB >> 8193363

Idiotypic vaccination against human B-cell lymphoma. Rescue of variable region gene sequences from biopsy material for assembly as single-chain Fv personal vaccines.

R E Hawkins1, D Zhu, M Ovecka, G Winter, T J Hamblin, A Long, F K Stevenson.   

Abstract

Idiotypic determinants on neoplastic B cells could provide tumor antigens for vaccination of patients with B-cell tumors. Because this approach requires an individual vaccine for each patient, simple methods for obtaining idiotypic antigen are desirable. Using polymerase chain reaction (PCR) with family-based V-gene and J-region primers, the variable region genes of heavy and light chains (VH and VL) of Ig have been obtained from biopsy material from 13 patients with B-cell tumors. In each case, analysis of random clones derived from the PCR product showed repeated, clonally-related sequences, whereas normal lymphoid tissue generated no repeated sequences. In 3/3 cases, the repeated sequences were found to be the same as those in a tumor-derived hybridoma. Mutational patterns in the V-genes differed among the tumors, with follicular lymphoma tending to be more highly mutated. The individual VH and VL sequences have been assembled with a flexible linker sequence to encode single-chain Fv (scFv). The scFv sequences can be cloned into bacterial expression vectors to produce protein, or into vectors suitable for direct vaccination using naked DNA. In a model system, expressed scFv protein retained all idiotypic determinants defined by a panel of five anti-idiotypic monoclonal antibodies (MoAbs). Similarly, expressed scFv proteins from two patients were shown to react with anti-idiotypic antibodies. This approach allows production of potential vaccines from surgical biopsies within 2 to 3 weeks.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8193363

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  21 in total

Review 1.  Vaccination strategies for lymphomas.

Authors:  Mohammed M Dar; Larry W Kwak
Journal:  Curr Oncol Rep       Date:  2003-09       Impact factor: 5.075

2.  Maleimide conjugation markedly enhances the immunogenicity of both human and murine idiotype-KLH vaccines.

Authors:  Kamran Kafi; David J Betting; Reiko E Yamada; Michael Bacica; Kristopher K Steward; John M Timmerman
Journal:  Mol Immunol       Date:  2008-11-28       Impact factor: 4.407

Review 3.  Developing idiotype vaccines for lymphoma: from preclinical studies to phase III clinical trials.

Authors:  Hyun Jun Park; Sattva S Neelapu
Journal:  Br J Haematol       Date:  2008-04-13       Impact factor: 6.998

4.  Cloning murine antibody V-genes with non-degenerate primers and conversion to a recombinant antibody format.

Authors:  Magdalena Bialon; Ludmila Schellenberg; Nicolas Herzog; Stefan Kraus; Hannah Jörißen; Rainer Fischer; Christoph Stein; Jörg Nähring; Stefan Barth; Christiane Püttmann
Journal:  Monoclon Antib Immunodiagn Immunother       Date:  2014-12

5.  The antigen-binding domain of a human IgG-anti-F(ab')2 autoantibody.

Authors:  M Welschof; P Terness; S M Kipriyanov; D Stanescu; F Breitling; H Dörsam; S Dübel; M Little; G Opelz
Journal:  Proc Natl Acad Sci U S A       Date:  1997-03-04       Impact factor: 11.205

6.  Insight into the potential for DNA idiotypic fusion vaccines designed for patients by analysing xenogeneic anti-idiotypic antibody responses.

Authors:  Francesco Forconi; Catherine A King; Surinder S Sahota; Christopher K Kennaway; Nigel H Russell; Freda K Stevenson
Journal:  Immunology       Date:  2002-09       Impact factor: 7.397

Review 7.  DNA vaccines: developing new strategies against cancer.

Authors:  Daniela Fioretti; Sandra Iurescia; Vito Michele Fazio; Monica Rinaldi
Journal:  J Biomed Biotechnol       Date:  2010-03-28

8.  Cancer immunotherapy using Listeria monocytogenes and listerial virulence factors.

Authors:  Laurence M Wood; Patrick D Guirnalda; Matthew M Seavey; Yvonne Paterson
Journal:  Immunol Res       Date:  2008       Impact factor: 2.829

Review 9.  Harnessing DNA-induced immune responses for improving cancer vaccines.

Authors:  Andrés A Herrada; Nicole Rojas-Colonelli; Paula González-Figueroa; Jonathan Roco; César Oyarce; Maarten A Ligtenberg; Alvaro Lladser
Journal:  Hum Vaccin Immunother       Date:  2012-10-30       Impact factor: 3.452

10.  Engineering a single-chain Fv antibody to alpha v beta 6 integrin using the specificity-determining loop of a foot-and-mouth disease virus.

Authors:  Heide Kogelberg; Berend Tolner; Gareth J Thomas; Danielle Di Cara; Shane Minogue; Bala Ramesh; Serena Sodha; Dan Marsh; Mark W Lowdell; Tim Meyer; Richard H J Begent; Ian Hart; John F Marshall; Kerry Chester
Journal:  J Mol Biol       Date:  2008-07-16       Impact factor: 5.469

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.